Click for best price
PD1 PDL1 Immunotherapy Market Size, Share 2022
This report contains market size and forecasts of PD-1 and PD-L1 Immunotherapy in Global, including the following market information:
Global PD-1 and PD-L1 Immunotherapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global PD-1 and PD-L1 Immunotherapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
PD-1 inhibitor Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of PD-1 and PD-L1 Immunotherapy include AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer, Roche, Novartis, Jiangsu HengRui Medicine and Innovent, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the PD-1 and PD-L1 Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-1 and PD-L1 Immunotherapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, by Type, 2021 (%)
PD-1 inhibitor
PD-L1 inhibitor
Global PD-1 and PD-L1 Immunotherapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, by Application, 2021 (%)
Solid Tumors
Blood-related Tumors
Global PD-1 and PD-L1 Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global PD-1 and PD-L1 Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies PD-1 and PD-L1 Immunotherapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies PD-1 and PD-L1 Immunotherapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bristol-Myers Squibb
F. Hoffmann-La Roche
Merck
Pfizer
Roche
Novartis
Jiangsu HengRui Medicine
Innovent
Eli Lilly
GlaxoSmithKline
| Report Attributes |
Report Details |
| Report Title |
PD-1 and PD-L1 Immunotherapy Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
69 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 PD-1 and PD-L1 Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PD-1 and PD-L1 Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PD-1 and PD-L1 Immunotherapy Overall Market Size
2.1 Global PD-1 and PD-L1 Immunotherapy Market Size: 2021 VS 2028
2.2 Global PD-1 and PD-L1 Immunotherapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top PD-1 and PD-L1 Immunotherapy Players in Global Market
3.2 Top Global PD-1 and PD-L1 Immunotherapy Companies Ranked by Revenue
3.3 Global PD-1 and PD-L1 Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 PD-1 and PD-L1 Immunotherapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies PD-1 and PD-L1 Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global PD-1 and PD-L1 Immunotherapy Market Size Markets, 2021 & 2028
4.1.2 PD-1 inhibitor
4.1.3 PD-L1 inhibitor
4.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2022
4.2.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2023-2028
4.2.3 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global PD-1 and PD-L1 Immunotherapy Market Size, 2021 & 2028
5.1.2 Solid Tumors
5.1.3 Blood-related Tumors
5.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2022
5.2.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2023-2028
5.2.3 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global PD-1 and PD-L1 Immunotherapy Market Size, 2021 & 2028
6.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2022
6.2.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2023-2028
6.2.3 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
6.3.2 US PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
6.4.2 Germany PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4.3 France PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4.4 U.K. PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4.5 Italy PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4.6 Russia PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4.7 Nordic Countries PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.4.8 Benelux PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
6.5.2 China PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.5.3 Japan PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.5.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.5.5 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.5.6 India PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
6.6.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.6.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028
6.7.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.7.3 Israel PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.7.4 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
6.7.5 UAE PD-1 and PD-L1 Immunotherapy Market Size, 2017-2028
7 Players Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Corporate Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.1.5 AstraZeneca Key News
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Corporate Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.2.5 Bristol-Myers Squibb Key News
7.3 F. Hoffmann-La Roche
7.3.1 F. Hoffmann-La Roche Corporate Summary
7.3.2 F. Hoffmann-La Roche Business Overview
7.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.3.5 F. Hoffmann-La Roche Key News
7.4 Merck
7.4.1 Merck Corporate Summary
7.4.2 Merck Business Overview
7.4.3 Merck PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.4.5 Merck Key News
7.5 Pfizer
7.5.1 Pfizer Corporate Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.5.5 Pfizer Key News
7.6 Roche
7.6.1 Roche Corporate Summary
7.6.2 Roche Business Overview
7.6.3 Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.6.5 Roche Key News
7.7 Novartis
7.7.1 Novartis Corporate Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.7.5 Novartis Key News
7.8 Jiangsu HengRui Medicine
7.8.1 Jiangsu HengRui Medicine Corporate Summary
7.8.2 Jiangsu HengRui Medicine Business Overview
7.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.8.5 Jiangsu HengRui Medicine Key News
7.9 Innovent
7.9.1 Innovent Corporate Summary
7.9.2 Innovent Business Overview
7.9.3 Innovent PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.9.5 Innovent Key News
7.10 Eli Lilly
7.10.1 Eli Lilly Corporate Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.10.5 Eli Lilly Key News
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Corporate Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2017-2022)
7.11.5 GlaxoSmithKline Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. PD-1 and PD-L1 Immunotherapy Market Opportunities & Trends in Global Market
Table 2. PD-1 and PD-L1 Immunotherapy Market Drivers in Global Market
Table 3. PD-1 and PD-L1 Immunotherapy Market Restraints in Global Market
Table 4. Key Players of PD-1 and PD-L1 Immunotherapy in Global Market
Table 5. Top PD-1 and PD-L1 Immunotherapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global PD-1 and PD-L1 Immunotherapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies PD-1 and PD-L1 Immunotherapy Product Type
Table 9. List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - PD-1 and PD-L1 Immunotherapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca PD-1 and PD-L1 Immunotherapy Product Offerings
Table 32. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Corporate Summary
Table 34. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product Offerings
Table 35. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 36. F. Hoffmann-La Roche Corporate Summary
Table 37. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product Offerings
Table 38. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 39. Merck Corporate Summary
Table 40. Merck PD-1 and PD-L1 Immunotherapy Product Offerings
Table 41. Merck PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 42. Pfizer Corporate Summary
Table 43. Pfizer PD-1 and PD-L1 Immunotherapy Product Offerings
Table 44. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 45. Roche Corporate Summary
Table 46. Roche PD-1 and PD-L1 Immunotherapy Product Offerings
Table 47. Roche PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 48. Novartis Corporate Summary
Table 49. Novartis PD-1 and PD-L1 Immunotherapy Product Offerings
Table 50. Novartis PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 51. Jiangsu HengRui Medicine Corporate Summary
Table 52. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product Offerings
Table 53. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 54. Innovent Corporate Summary
Table 55. Innovent PD-1 and PD-L1 Immunotherapy Product Offerings
Table 56. Innovent PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 57. Eli Lilly Corporate Summary
Table 58. Eli Lilly PD-1 and PD-L1 Immunotherapy Product Offerings
Table 59. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
Table 60. GlaxoSmithKline Corporate Summary
Table 61. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product Offerings
Table 62. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. PD-1 and PD-L1 Immunotherapy Segment by Type in 2021
Figure 2. PD-1 and PD-L1 Immunotherapy Segment by Application in 2021
Figure 3. Global PD-1 and PD-L1 Immunotherapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global PD-1 and PD-L1 Immunotherapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global PD-1 and PD-L1 Immunotherapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by PD-1 and PD-L1 Immunotherapy Revenue in 2021
Figure 8. By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 12. US PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 16. Germany PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 17. France PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 24. China PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 28. India PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 30. Brazil PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2017-2028
Figure 33. Turkey PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE PD-1 and PD-L1 Immunotherapy Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Merck PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Pfizer PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Roche PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Innovent PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
